Leerink Partners maintains Insulet at Market Perform, raises price target to $167 from $143
Leerink Partners kept Insulet at Market Perform, raising its price target to $167 from $143, a 16.8% increase. This implies 1.2% upside from the Nov 4 close of $165.02. Recent analyst targets for Insulet range from $150 to $200.
How this was made

The 30-second read
Why it matters
Analyst price target increase could prompt short covering and new buying.
Market read
Analyst upgrade may influence short-term price action for PINS.
What to watch
Potential competitive pressures and reimbursement challenges.
Background
Insulet Corp. (PINS) is a medical device company specializing in insulin pumps.
Market effects
May boost sentiment in the medical device sector.
Limited to US markets where Insulet trades.
Low global impact.
Counterpoint
Target raise may be premature if upcoming earnings miss expectations.
Key entities
- analyst firmLeerink Partners
Equity research firm that raised the price target.
- companyInsulet Corp.
Manufacturer of insulin delivery devices.

